Theriva Biologics licenses SYN-020 to Rasayana for $300K upfront, up to $38M milestones

Theriva Biologics, Inc.

Upfront payment of $300,000 received; eligible for $16M development/regulatory and $22M sales milestones.
Tiered single-digit royalties on net sales of SYN-020; Rasayana assumes all development and commercialization costs.
SYN-020 is an oral IAP enzyme with Phase 1 safety data; Rasayana plans Phase 2 testing.
Theriva to focus on lead pancreatic cancer program VCN-01 following out-license.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Theriva Biologics, Inc. entered into Agreement with Rasayana Therapeutics, Inc. valued at $300,000 (effective 2026-02-18).

Action: entry
Agreement: license
Counterparty: Rasayana Therapeutics, Inc.
Value: $300,000
Effective: 2026-02-18

Exact text from the filing

On February 18, 2026 (the “Effective Date”), Theriva Biologics, Inc. (the “Company”) entered into a license agreement (the “Agreement”) with Rasayana Therapeutics, Inc. (“Rasayana”)

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Theriva Biologics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-016792

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.